To Strengthen Collaboration with Medical Institutions

Medipost Invites Jeongseok Hospital's Chief Director Seonghee Jeong

CARTISTEM, the Only Stem Cell Therapy Approved as a Specialized Medicine for Cartilage Regeneration

Medipost and Jeongseok Hospital Hold Session to Share CARTISTEM Treatment Expertise View original image

Medipost (CEO Oh Wonil), a biotechnology company, announced on the 30th that it held a discussion session on the 23rd by inviting Seonghee Jeong, the Chief Director of the Joint Center at Jeongseok Hospital, to share CARTISTEM® treatment cases and clinical experience.


According to Medipost, this program was designed to expand academic exchange with collaborating medical professionals and to share real-world clinical experiences with CARTISTEM. Chief Director Seonghee Jeong serves as a Medipost advisory member and has accumulated significant clinical experience. Jeongseok Hospital is known as one of the most active institutions in Nowon-gu for performing CARTISTEM procedures.


On this occasion, Chief Director Jeong visited the Medipost headquarters to tour the research facilities and production sites, and exchanged opinions on the direction of CARTISTEM treatment with company officials.


In the subsequent lecture, the characteristics of CARTISTEM, a cord blood-derived mesenchymal stem cell therapy, were introduced, and real-world application experiences from actual clinical practice were shared. In particular, by presenting patient-tailored treatment strategies and the long-term course following treatment based on actual case studies, the session was evaluated as having enhanced participants' clinical understanding.


The process of accumulating various procedural know-how through close communication with experienced medical professionals is expected to enhance the competitiveness of the domestic regenerative medicine industry going forward.


A Medipost representative stated, "It was a meaningful occasion to share treatment experience and expertise accumulated at the clinical site, and to broaden exchanges among healthcare professionals," adding, "We will continue to focus on academic exchange with collaborating medical staff and strive to improve patient treatment outcomes."



Meanwhile, Medipost has designated Jeongseok Hospital as a research partner for stem cell studies, appointed Chief Director Seonghee Jeong as a CARTISTEM advisory committee member, and also presented a plaque of appreciation. Both parties plan to continue cooperation not only in sharing clinical experience and academic exchange on CARTISTEM, but also in stem cell research and education.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing